http://purl.org/np/RAMgA3pDhU... RAMgA3pDhU

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate predicate

https://w3id.org/biolink/vocab/treats treats

0000-0002-7641-6446

2021-08-16T20:58:07.416Z

http://purl.org/np/RAMgA3pDhU... RAMgA3pDhU

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/2000/01/rdf-schema#label label

Although antidepressants are not the first-line prophylactic strategy for patients with migraine, several clinical trials have proven their effectiveness in the treatment of migraine and related headache disorders (Koch and Jurgens, 2009). Especially TCAs: amitriptyline (Couch and Hassanein, 1979; Jackson et al., 2010; Kalita et al., 2013) and nortriptyline (Holroyd et al., 2001; Jackson et al., 2010) have the best evidence for use in migraine prevention. When amitriptyline is not tolerated by patients, treatment is continued with nortriptyline (Burch, 2019).

0000-0002-7641-6446

2021-08-16T20:58:07.416Z

http://purl.org/np/RAMgA3pDhU... RAMgA3pDhU

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

https://w3id.org/biolink/vocab/publications publications

https://pubmed.ncbi.nlm.nih.gov/31622593 pubmed.ncbi.nlm.nih.gov/31622593

0000-0002-7641-6446

2021-08-16T20:58:07.416Z

http://purl.org/np/RAMgA3pDhU... RAMgA3pDhU

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#subject subject

https://identifiers.org/DRUGBANK:DB00321 DRUGBANK:DB00321

0000-0002-7641-6446

2021-08-16T20:58:07.416Z

http://purl.org/np/RAMgA3pDhU... RAMgA3pDhU

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#object object

http://purl.obolibrary.org/obo/MONDO_0005277 MONDO_0005277

0000-0002-7641-6446

2021-08-16T20:58:07.416Z

http://purl.org/np/RAMgA3pDhU... RAMgA3pDhU

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

https://w3id.org/biolink/vocab/has_population_context has_population_context

http://purl.org/np/RAMgA3pDhU...#context context

0000-0002-7641-6446

2021-08-16T20:58:07.416Z

http://purl.org/np/RAMgA3pDhU... RAMgA3pDhU

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

https://w3id.org/biolink/vocab/relation relation

https://w3id.org/um/neurodkg/OffLabelIndication OffLabelIndication

0000-0002-7641-6446

2021-08-16T20:58:07.416Z

http://purl.org/np/RAMgA3pDhU... RAMgA3pDhU

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/2000/01/rdf-schema#label label

Although antidepressants are not the first-line prophylactic strategy for patients with migraine, several clinical trials have proven their effectiveness in the treatment of migraine and related headache disorders (Koch and Jurgens, 2009). Especially TCAs: amitriptyline (Couch and Hassanein, 1979; Jackson et al., 2010; Kalita et al., 2013) and nortriptyline (Holroyd et al., 2001; Jackson et al., 2010) have the best evidence for use in migraine prevention. When amitriptyline is not tolerated by patients, treatment is continued with nortriptyline (Burch, 2019).

0000-0002-7641-6446

2021-08-16T20:58:07.416Z

http://purl.org/np/RAMgA3pDhU... RAMgA3pDhU

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

https://w3id.org/biolink/vocab/provided_by provided_by

https://w3id.org/um/NeuroDKG NeuroDKG

0000-0002-7641-6446

2021-08-16T20:58:07.416Z

http://purl.org/np/RAMgA3pDhU... RAMgA3pDhU

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#type type

http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement Statement

0000-0002-7641-6446

2021-08-16T20:58:07.416Z